Abbott's (ABT) Innovations Aid, Macroeconomic Issues Stay

Abbott’s (ABT) Established Pharmaceuticals Division (EPD) businesses are expected to grow in the coming quarters, banking on new launches. However, the business environment continues to be challenging globally. The stock carries a Zacks Rank #3 (Hold) currently.Abbott is expanding its Diagnostics business foothold (consisting of 24% of the company’s total revenues in the third quarter of 2023). Over the past few quarters, there has been a decline in demand for Abbott’s rapid diagnostic tests to detect COVID ...